Aardvark Therapeutics
AARD
66 hedge funds and large institutions have $141M invested in Aardvark Therapeutics in 2025 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 27 increasing their positions, 9 reducing their positions, and 6 closing their positions.
283% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 6
200% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 9
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
35% more funds holding
Funds holding: 49 → 66 (+17)
12% more capital invested
Capital invested by funds: $126M → $141M (+$15.3M)
5.76% more ownership
Funds ownership: 43.61% → 49.36% (+5.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.93M |
| 2 |
Millennium Management
New York
|
+$2.04M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.02M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.3M |
| 5 |
CC
Centiva Capital
New York
|
+$1.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.65M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$2.54M |
| 3 |
CAM
Cresset Asset Management
Chicago,
Illinois
|
-$1.88M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$881K |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$508K |
AARD Hedge Fund Activity: Q4 2025 in Review
66 of the 8,275 institutional investors tracked by Wall St. Rank reported a position in Aardvark Therapeutics (AARD) for Q4 2025, worth a combined $141M — up 12% from $126M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new AARD positions and 6 closed out — a net gain of 17 holders — while 27 added to existing stakes and 9 trimmed.
The largest buyer was BlackRock, adding an estimated $5.93M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $4.65M sold.
- 66 institutional investors held Aardvark Therapeutics (AARD) as of Q4 2025, up from 49 in Q3 2025.
- Funds reported $141M of Aardvark Therapeutics stock for Q4 2025, up 12% quarter-over-quarter.
- 23 funds opened new Aardvark Therapeutics positions in Q4 2025 and 6 closed out, a net change of +17 holders.
- The largest Aardvark Therapeutics buyer in Q4 2025 was BlackRock, an estimated $5.93M added.
- The largest Aardvark Therapeutics seller in Q4 2025 was Adage Capital Partners, an estimated $4.65M sold.
Based on aggregated 13F filings for Q4 2025.